"By combining our scientific expertise with the KDA's deep understanding of patient needs, we are confident in our ability to develop a transformative therapy for KD." "KDA is excited to partner with ...

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

The American Society for Radiation Oncology (ASTRO) issued today an updated clinical guideline for physicians who use ...

A Mount Sinai team has developed a blood-brain barrier-crossing conjugate (BCC) platform, enabling therapeutic molecules to ...

A large, multiyear study conducted by Illumina, Providence, and Microsoft Research has shown that a comprehensive genomic profiling (CGP) panel, which can assess more than 500 genetic variations in ...

Rznomics, Inc. announced to secure its expanded access program (EAP) from the United States Food and Drug Administration (FDA) for RZ-001, ...

Gene Synthesis Market. The global gene synthesis market is poised for extraordinary expansion, with its valuation projected ...

Seemal Desai, M.D., FAAD, discusses how treatment safety and effectiveness must be carefully evaluated through monitoring ...

Ractigen's RAG-21, a treatment for ALS linked to mutations in the FUS gene, has been granted orphan drug designation in the U ...

CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The ...

Capsida Biotherapeutics ("Capsida"), a leading fully integrated next-generation gene therapy company developing treatments ...